XTNT logo

Xtant Medical Holdings, Inc. Stock Price

NYSEAM:XTNT Community·US$111.3m Market Cap
  • 1 Narratives written by author
  • 0 Comments on narratives written by author
  • 6 Fair Values set on narratives written by author

XTNT Share Price Performance

US$0.77
0.41 (115.24%)
US$1.50
Fair Value
US$0.77
0.41 (115.24%)
48.6% undervalued intrinsic discount
US$1.50
Fair Value
Price US$0.77
AnalystConsensusTarget US$1.50

XTNT Community Narratives

AnalystConsensusTarget·
Fair Value US$1.5 48.6% undervalued intrinsic discount

Biologics Focus And Divestiture Of Noncore Assets Will Drive Long Term Earnings Power

0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
US$1.5
48.6% undervalued intrinsic discount
Revenue
-4.64% p.a.
Profit Margin
1.94%
Future PE
122.17x
Price in 2028
US$1.91

Trending Discussion

Updated Narratives

XTNT logo

Biologics Focus And Divestiture Of Noncore Assets Will Drive Long Term Earnings Power

Fair Value: US$1.5 48.6% undervalued intrinsic discount
1 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative

Snowflake Analysis

Excellent balance sheet with acceptable track record.

1 Risk
2 Rewards

Xtant Medical Holdings, Inc. Key Details

US$133.1m

Revenue

US$50.5m

Cost of Revenue

US$82.5m

Gross Profit

US$80.8m

Other Expenses

US$1.8m

Earnings

Last Reported Earnings
Sep 30, 2025
Next Reporting Earnings
n/a
0.013
62.02%
1.32%
57.0%
View Full Analysis

About XTNT

Founded
n/a
Employees
225
CEO
Sean Browne
WebsiteView website
xtantmedical.com

Xtant Medical Holdings, Inc. provides regenerative medicine products and medical devices for orthopedic and neurological surgeons in the United States and internationally. The company offers OsteoSponge, a natural scaffold for cellular in-growth; OsteoSelect DBM Putty, which can be compressed into bony voids; OsteoSelect PLUS DBM Putty to deliver handling properties and ensure patient safety through validated and terminal sterilization; 3Demin, a family of allografts that maximizes osteoconductivity and the osteoinductive potential of human bone; OsteoFactor, a processed allograft that contains retained growth factors found within the endosteum layer of allograft bone; OsteoVive Plus, an aseptically processed and viable bone allograft; and nanOss products that provide osteoconductive nano-structured hydroxyapatite and an engineered extracellular matrix bioscaffold collagen carrier. It also provides sports allografts for anterior and posterior cruciate ligament repairs, anterior cruciate ligament reconstruction, and meniscal repair; milled spinal allografts for cortical bone milled to desired shapes and dimensions; and traditional allografts for orthopedics, neurology, podiatry, oral/maxillofacial, genitourinary, and plastic/reconstructive applications. In addition, the company offers cervical products comprising Spider cervical plating, Streamline OCT, and CervAlign systems; thoracolumbar products consisting of Axle-X interspinous fusion, Streamline MIS spinal fixation, Streamline TL spinal fixation, and HPS 2.0 hybrid performance systems; and Silex sacroiliac joint fusion systems. Further, it provides interbody products comprising Calix for cervical and thoracolumbar applications, Irix-C Cervical and Irix-A lumbar integrated dusion systems, and Fortilink implants; and interlaminar stabilization products, such as Coflex device for lumbar spinal stenosis; and CoFix implants for back and disc pain. Xtant Medical Holdings, Inc. is headquartered in Belgrade, Montana.

Recent XTNT News & Updates

Recent updates

No updates